Durvalumab Consolidation after Chemoradiation Therapy for Limited Stage SCLC in China

Trial Identifier: D419QR00019
Sponsor: AstraZeneca
Start Date: November 2025
Primary Completion Date: September 2028
Study Completion Date: September 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China
China Cangzhou, China
China Changsha, China
China Dongguan, China
China Fuzhou, China
China Guangzhou, China
China Huzhou, China
China Jinan, China, 250117
China Jinan, China
China Jinzhou, China
China Nanjing, China
China Nanning, China
China Ningbo, China
China Shanghai, China
China Shenyang, China
China Shenzhen, China
China Shijiazhuang, China
China Taiyuan, China
China Tianjing, China
China Wuhan, China
China Yangzhou, China
China Zhengzhou, China